Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors

被引:150
作者
Sumida, SM
Truitt, DM
Kishko, MG
Arthur, JC
Jackson, SS
Gorgone, DA
Lifton, MA
Koudstaal, W
Pau, MG
Kostense, S
Havenga, MJE
Goudsmit, J
Letvin, NL
Barouch, DH
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Sch Med, Boston, MA 02215 USA
[2] Crucell Holland, Leiden, Netherlands
关键词
D O I
10.1128/JVI.78.6.2666-2673.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The high prevalence of preexisting immunity to adenovirus serotype 5 (Ad5) in human populations will likely limit the inummogenicity and clinical utility of recombinant Ad5 vector-based vaccines for human immunodeficiency virus type 1 and other pathogens. Ad5-specific neutralizing antibodies (NAbs) are thought to contribute substantially to anti-Ad5 immunity, but the potential importance of Ad5-specific T lymphocytes in this setting has not been fully characterized. Here we assess the relative contributions of Ad5-specific Immoral and cellular immune responses in blunting the immunogenicity of a rAd5-Env vaccine in mice. Adoptive transfer of Ad5-specific NAbs resulted in a dramatic abrogation of Env-specific immune. responses following immunization with rAd5-Env. Interestingly, adoptive transfer of Ad5-specific CD8(+) T lymphocytes also resulted in a significant and durable suppression of rAd5-Env immunogenicity. These data demonstrate that NAbs and CD8(+) T lymphocytes both contribute to immunity to Ad5. Novel adenovirus vectors that are currently being developed to circumvent the problem of preexisting anti-Ad5 immunity should therefore be designed to evade both Immoral and cellular Ad5-specific immune responses.
引用
收藏
页码:2666 / 2673
页数:8
相关论文
共 32 条
[11]   Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver [J].
Jooss, K ;
Ertl, HCJ ;
Wilson, JM .
JOURNAL OF VIROLOGY, 1998, 72 (04) :2945-2954
[12]  
KassEisler A, 1996, GENE THER, V3, P154
[13]   ERADICATION OF ADENOVIRUS E1-INDUCED TUMORS BY E1A-SPECIFIC CYTO-TOXIC LYMPHOCYTES-T [J].
KAST, WM ;
OFFRINGA, R ;
PETERS, PJ ;
VOORDOUW, AC ;
MELOEN, RH ;
VANDEREB, AJ ;
MELIEF, CJM .
CELL, 1989, 59 (04) :603-614
[14]   Prospects for vaccine protection against HIV-1 infection and AIDS [J].
Letvin, NL ;
Barouch, DH ;
Montefiori, DC .
ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :73-99
[15]   Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype [J].
Mack, CA ;
Song, WR ;
Carpenter, H ;
Wickham, TJ ;
Kovesdi, I ;
Harvey, BG ;
Magovern, CJ ;
Isom, OW ;
Rosengart, T ;
FalckPedersen, E ;
Hackett, NR ;
Crystal, RG ;
Mastrangeli, A .
HUMAN GENE THERAPY, 1997, 8 (01) :99-109
[16]   ''Sero-switch'' adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype [J].
Mastrangeli, A ;
Harvey, BG ;
Yao, J ;
Wolff, G ;
Kovesdi, I ;
Crystal, RG ;
FalckPedersen, E .
HUMAN GENE THERAPY, 1996, 7 (01) :79-87
[17]   Immune response to recombinant adenovirus in humans: Capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes [J].
Molinier-Frenkel, V ;
Gawery-Segard, H ;
Mentali, M ;
Le Boulaire, C ;
Ribault, S ;
Boulanger, P ;
Tursz, T ;
Guillet, JG ;
Farace, F .
JOURNAL OF VIROLOGY, 2000, 74 (16) :7678-7682
[18]   The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope [J].
Olive, M ;
Eisenlohr, L ;
Flomenberg, N ;
Hsu, S ;
Flomenberg, P .
HUMAN GENE THERAPY, 2002, 13 (10) :1167-1178
[19]   Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity [J].
Shiver, JW ;
Fu, TM ;
Chen, L ;
Casimiro, DR ;
Davies, ME ;
Evans, RK ;
Zhang, ZQ ;
Simon, AJ ;
Trigona, WL ;
Dubey, SA ;
Huang, LY ;
Harris, VA ;
Long, RS ;
Liang, XP ;
Handt, L ;
Schleif, WA ;
Zhu, L ;
Freed, DC ;
Persaud, NV ;
Guan, L ;
Punt, KS ;
Tang, A ;
Chen, MC ;
Wilson, KA ;
Collins, KB ;
Heidecker, GJ ;
Fernandez, VR ;
Perry, HC ;
Joyce, JG ;
Grimm, KM ;
Cook, JC ;
Keller, PM ;
Kresock, DS ;
Mach, H ;
Troutman, RD ;
Isopi, LA ;
Williams, DM ;
Xu, Z ;
Bohannon, KE ;
Volkin, DB ;
Montefiori, DC ;
Miura, A ;
Krivulka, GR ;
Lifton, MA ;
Kuroda, MJ ;
Schmitz, JE ;
Letvin, NL ;
Caulfield, MJ ;
Bett, AJ ;
Youil, R .
NATURE, 2002, 415 (6869) :331-335
[20]   Extensive cross-reactivity of adenovirus-specific cytotoxic T cells [J].
Smith, CA ;
Woodruff, LS ;
Rooney, C ;
Kitchingman, GR .
HUMAN GENE THERAPY, 1998, 9 (10) :1419-1427